Evidence map›Paper›PMID 29644009›Full record

ArticleOncotarget2018

Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both

Nobuhiro Saito, Yoshihiro Shirai, Tadashi Uwagawa, Takashi Horiuchi, Hiroshi Sugano, Koichiro Haruki, Hiroaki Shiba, Toya Ohashi, Katsuhiko Yanaga

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nobuhiro SaitoDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Yoshihiro ShiraiDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Tadashi UwagawaDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Takashi HoriuchiDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Hiroshi SuganoDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Koichiro HarukiDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Hiroaki ShibaDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Toya OhashiDivision of Gene Therapy, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan.
Katsuhiko YanagaDepartment of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Jikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy with gemcitabine and nab-paclitaxel (gemcitabine/nab-paclitaxel) is recommended for unresectable pancreatic cancer. However, the therapeutic efficacy is attenuated by the antitumor agent-induced activation of nuclear factor-κB (NF-κB). Thalidomide inhibits NF-κB activation, therefore, we hypothesized that pomalidomide, a third-generation IMiD, would also inhibit NF-κB activation and enhance the antitumor effects of gemcitabine/nab-paclitaxel.

methods

resultsIn pomalidomide and gemcitabine/nab-paclitaxel group, gemcitabine/nab-paclitaxel-induced NF-κB activation was inhibited and apoptosis was enhanced in comparison with those in the other groups both

conclusionsPomalidomide enhanced the antitumor effect of gemcitabine/nab-paclitaxel by inhibition of NF-κB activation. This combination regimen would be a novel strategy for treating pancreatic cancer.

Indexed as

gemcitabine/nab-paclitaxelIMiDsNF-κBp53pancreatic cancer

Identifiers

PMID29644009
PMCPMC5884664
OpenAlexW2791287606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.